Scoop: Google’s GV spearheads the Spotlight syndicate — backing an upstart biotech aimed at ‘democratizing’ gene editing
CRISPR had no sooner started to shake the very foundations of drug development before its limitations began to loom large. Gene editing could change the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.